In drug development, speed is often discussed as a function of effort. Teams move faster. Timelines compress. Activities overlap. And yet, many programs still stall—sometimes at the very moment when momentum should be building.
That disconnect is familiar to anyone who has worked across development, manufacturing, and supply. Programs rarely slow down because a single task takes too long. More often, they slow down because decisions are made without enough visibility into what comes next.
The real determinants of speed sit at the seams.
Clinical plans advance without full awareness of manufacturing implications. Manufacturing strategies are defined before downstream supply realities are fully understood. Decisions that seem reasonable in isolation introduce friction later, when timelines are tighter and options are fewer.
None of this reflects a lack of capability. It reflects a lack of coordination at the right moments.
When development programs are structured around sequential handoffs, speed in one area can actually create drag in another. Teams find themselves revisiting decisions under pressure, adjusting plans late, or absorbing risk that could have been addressed earlier with better alignment.
By contrast, when coordination happens earlier—across functions, across phases, and across partners—execution tends to accelerate naturally. Decisions are sequenced with a clearer understanding of their downstream impact. Risks surface when there is still time to manage them deliberately. Tradeoffs are made consciously, rather than reactively.
This kind of coordination is less about process and more about behavior. It requires teams to share context freely, engage directly with one another, and operate with a shared view of the program rather than a narrow functional lens.
From the customer’s perspective, the difference is tangible. Progress feels steadier. Transitions between phases are less disruptive. Fewer decisions need to be revisited because fewer were made in isolation.
In complex development programs, velocity doesn’t come from pushing harder at the end. It comes from making progress predictable. Predictability is established through clear planning of the critical path and deliberate alignment across manufacturing, clinical, and regulatory functions. When these elements are connected early, execution becomes more consistent. Standard workflows guide progress, governance supports decision-making, and teams move forward with fewer resets. Coordination reduces the need for rework, allowing progress to build through disciplined planning rather than last-minute effort.
That reality has given rise to Thermo Fisher Scientific’s Accelerator™ Drug Development as a defining operating model of this moment. Built as a deeply integrated CDMO–CRO approach, it connects scientific, manufacturing, and clinical decisions within a single development pathway—so complexity is addressed upstream, rather than absorbed later under pressure.
To date, Accelerator™ Drug Development has supported hundreds of development programs for biotech and pharma customers, reflecting a growing recognition that speed, risk, and execution discipline must be addressed together, not sequentially.
